EQT

eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies that harness the key role of dendritic cells in the immune system. The company focuses on treating melanoma, triple-negative breast cancer, and infectious diseases through its innovative TriMix technology, which enhances the immune response. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA collaborates strategically with China Grand Pharmaceutical and Healthcare Holdings Limited to advance its research and development efforts. The company aims to lead in nucleic acid-based medicine, enabling partners to create new therapeutic options and improve patient outcomes.

ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customer experiences. From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people.

Storytel is a provider of audiobook and e-book streaming services, offering unlimited access to consumers across more than 20 markets. Founded in 2005, the company has established a strong presence in countries including Sweden, Denmark, Norway, the Netherlands, and Poland. Storytel's offerings allow users to explore a diverse range of genres, including detective stories and biographies, with available content in multiple languages such as Swedish, English, Arabic, Danish, and Finnish. The company operates through two main divisions: Streaming, which delivers subscription services under the Storytel and Mofibo brands, and Publishing, which includes notable publishing houses like Norstedts, Massolit, and B. Wahlstrom. Since 2015, Storytel has expanded its operations by publishing physical books, enhancing its role in the book and publishing sector.

Mollie is a payments platform based in Amsterdam, founded in 2004, that simplifies the integration of payment solutions for online businesses. Serving over 50,000 clients, the company supports a variety of local payment methods, including Mastercard, VISA, PayPal, and iDEAL, among others. Mollie's technology-driven approach allows merchants to easily implement payment systems through a simple yet powerful API, facilitating one-click payments, fraud monitoring, and real-time accounting. By streamlining the payment process, Mollie enables businesses to efficiently manage their finances and enhance revenue generation while minimizing operational complexities.

Desotec has pioneered the market for the purification of liquids and gases through mobile activated carbon filters. Desotec provides a filtration technology that enables its customers to comply with increased environmental regulations and sustainability requirements and to serve mission-critical filtration needs offering a flexible rental solution.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

Vico Therapeutics B.V., founded in 2019 and based in Leiden, the Netherlands, specializes in developing RNA modulating therapies aimed at treating rare neurological disorders. The company's primary focus is on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome. By discovering and delivering innovative therapies, Vico Therapeutics aims to address the unmet medical needs of patients suffering from these severe central nervous system disorders, thereby enhancing treatment options available to medical professionals.

ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customer experiences. From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people.

VarmX is a pharmaceutical spin-off from the Leiden University Medical Center focused on developing and manufacturing therapeutic proteins aimed at restoring blood clotting in patients experiencing severe bleeding. The company's lead product, PseudoXa, is a modified recombinant human coagulation factor X designed to work effectively in the presence of direct factor Xa anticoagulants like rivaroxaban, apixaban, and edoxaban. These anticoagulants are widely used for preventing and treating thrombosis and stroke but can lead to dangerous bleeding as a side effect. PseudoXa addresses this critical issue by providing a means to stop and prevent bleeding, thereby enhancing the safety of anticoagulant therapies for millions of patients worldwide.

Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, the Netherlands, specializing in cell-based immunotherapy products aimed at treating blood cancers and inherited blood disorders. The company is currently advancing K-NK002, which is undergoing Phase II clinical trials for blood cancer patients receiving haploidentical hematopoietic stem cell transplants with the post-transplant cyclophosphamide protocol. Additionally, Kiadis Pharma is developing K-NK003, currently in Phase I/II trials for patients with acute myeloid leukemia relapse or refractory cases. The preclinical product pipeline includes K-NK00X, a natural killer (NK) cell therapy candidate targeting various solid tumors. Kiadis Pharma also collaborates with several institutions, including Harbour BioMed and Erasmus Medical Center, to explore a combination of monoclonal antibodies and natural killer cells as a potential treatment for COVID-19. Founded in 1997, Kiadis Pharma is committed to addressing significant unmet medical needs in the treatment of blood-related conditions.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

AM Pharma B.V. is a biopharmaceutical company based in Bunnik, the Netherlands, focused on developing and commercializing novel therapeutics for inflammatory and infectious diseases. Established in 2000, the company specializes in pre-clinical and clinical development using endogenous proteins and peptides derived from the human body. Its key products include alkaline phosphatase, aimed at treating acute kidney injury and ulcerative colitis, and the immune response amplifying peptide hLF1-11, which targets drug-resistant hospital-acquired infections. AM Pharma is committed to providing innovative therapies that enhance patient quality of life by addressing critical medical needs.

Veritas Petroleum Services (VPS) is a provider of testing, inspection, and advisory solutions with laboratories strategically located in the Netherlands, Singapore, Houston, Fujairah, and Manchester. The company specializes in fuel quality testing, bunker quantity surveys, oil condition monitoring, and transformer oil testing, among other services. VPS assists marine, power, and renewable energy clients in optimizing their operational performance while ensuring compliance with environmental regulations. By delivering comprehensive testing services, VPS helps customers achieve measurable improvements in fuel management, reduce fuel costs, and enhance operational efficiency.

Banking Circle is a fully licensed financial technology platform specializing in cross-border banking transactions for global commerce. The company provides a suite of essential services, including multi-currency bank accounts, local clearing, and flexible business lending, which allow banks and payment businesses to operate without the need for their own extensive infrastructure. One of its notable offerings is the Banking Circle Virtual IBAN, enabling clients to access Faster Payments for more efficient financial transactions. By leveraging direct clearing access through established partner banks, Banking Circle facilitates low-cost international payments and settlements while ensuring compliance with financial regulations. This innovative approach allows financial services businesses to focus on serving their clients effectively and seizing market opportunities while bypassing outdated and costly banking systems. The company is backed by EQT VIII and EQT Ventures, indicating strong financial support and growth potential.

Dunlop Protective Footwear is a manufacturer of protective Wellington boots that provides comfortable and protective footwear to workers in Agriculture & Fishery, Food processing, Industry, and the Oil, Gas & Mining industry.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

Caiway is a telecommunications infrastructure company based in the Netherlands, specializing in broadband services for over 350,000 households and businesses. The company has expanded its fiber network into remote areas, enhancing connectivity for municipalities and homes. As a regional internet service provider, Caiway offers a variety of services, including broadband, television, and telephony, delivered through its cable and fiber infrastructure. Major regions within Caiway's operational footprint include Westland, Schiedam, and Almelo, where it aims to provide reliable networking and high-quality service to its customers.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

DentConnect is a fast-growing platform of dental clinics, with activities in the Netherlands, Belgium, Denmark, Germany and Italy. DentConnect is headquartered in the Netherlands and serves over one million patients through its pan-European network of over 220 clinics. DentConnect acts as a multi-functional service organization for these clinics, allowing the dentists to fully focus on providing patients with the best possible care. DentConnect Shared Service Center supports and facilitates dentists with HR, Finance and administration, quality and care management, procurement, marketing and communication and general management.

Desotec has pioneered the market for the purification of liquids and gases through mobile activated carbon filters. Desotec provides a filtration technology that enables its customers to comply with increased environmental regulations and sustainability requirements and to serve mission-critical filtration needs offering a flexible rental solution.

Delta Fiber is a telecom company that provides internet, television, telephony and mobile services to consumers and businesses.

Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.

Onward is a medical technology company focused on developing therapies aimed at enabling functional recovery for individuals with spinal cord injuries. The company is creating an Implantable Neuro-stimulation System (INS) that features real-time motion feedback and utilizes training tools for rehabilitation. Onward has developed two platforms for neurostimulation: ARCIM, an implantable system, and ARCEX, a non-invasive transcutaneous system. To establish its customer base, Onward has targeted the United States and four European markets, namely Germany, France, the United Kingdom, and the Netherlands.

eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies that harness the key role of dendritic cells in the immune system. The company focuses on treating melanoma, triple-negative breast cancer, and infectious diseases through its innovative TriMix technology, which enhances the immune response. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA collaborates strategically with China Grand Pharmaceutical and Healthcare Holdings Limited to advance its research and development efforts. The company aims to lead in nucleic acid-based medicine, enabling partners to create new therapeutic options and improve patient outcomes.

ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customer experiences. From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people.

Pharvaris is a clinical-stage company dedicated to the discovery and development of therapies for rare diseases, particularly focusing on hereditary angioedema (HAE) and other conditions mediated by bradykinin. The company is advancing an oral bradykinin B2 receptor antagonist, with its lead candidate, PHA121, currently undergoing Phase 1 clinical trials. Pharvaris aims to provide new treatment options that offer alternatives to injected therapies for all sub-types of HAE. The company was co-founded by key individuals involved in the development of icatibant, a previously established treatment for HAE, ensuring a strong foundation in this therapeutic area.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Neuravi Limited, founded in 2009 and headquartered in Galway, Ireland, specializes in the design and development of innovative clot retrieval devices aimed at restoring blood flow in patients experiencing ischemic strokes caused by arterial blockages in the brain. The company's primary product, the EmboTrap revascularization device, is utilized in the treatment of acute ischemic strokes and is available in several European countries, including Belgium, Denmark, France, Germany, and Spain. Neuravi's focus on neuro-interventional therapies is backed by extensive research into the mechanisms of stroke, particularly regarding the capture and removal of clots, which enhances treatment efficacy and improves patient outcomes. The company collaborates with international researchers and clinicians to foster the development of new solutions for this critical medical challenge. As of April 2017, Neuravi operates as a subsidiary of DePuy Ireland Unlimited Company.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

Xeltis is a clinical-stage medical device company focused on transforming cardiovascular treatment through innovative restorative technologies. The company has developed advanced polymer-based devices, including bioabsorbable heart valves and implantable small diameter blood vessels, intended for hemodialysis vascular access and coronary artery bypass graft surgery. These devices leverage proprietary technology to facilitate endogenous tissue restoration, allowing the body to naturally regenerate the complex structures being replaced. Xeltis emerged from the merger of two university spin-offs from the Netherlands and Switzerland and operates in both the Netherlands and the USA. The company is backed by several venture capital firms and has secured significant funding from the European Investment Bank and the European Innovation Council Accelerator. Currently, Xeltis is conducting ongoing clinical trials to advance its restorative cardiovascular solutions.

Bureau van Dijk specializes in providing comprehensive company information products, primarily focused on private companies and corporate ownership structures. The firm aggregates, cleanses, integrates, and analyzes essential business data, delivering it to clients in the finance, corporate, and public sectors. Through its proprietary software, Bureau van Dijk enables clients to work more efficiently and make well-informed decisions. The company collaborates with various renowned information providers to enhance its offerings and maintain a high standard of data quality.

Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, the Netherlands, specializing in cell-based immunotherapy products aimed at treating blood cancers and inherited blood disorders. The company is currently advancing K-NK002, which is undergoing Phase II clinical trials for blood cancer patients receiving haploidentical hematopoietic stem cell transplants with the post-transplant cyclophosphamide protocol. Additionally, Kiadis Pharma is developing K-NK003, currently in Phase I/II trials for patients with acute myeloid leukemia relapse or refractory cases. The preclinical product pipeline includes K-NK00X, a natural killer (NK) cell therapy candidate targeting various solid tumors. Kiadis Pharma also collaborates with several institutions, including Harbour BioMed and Erasmus Medical Center, to explore a combination of monoclonal antibodies and natural killer cells as a potential treatment for COVID-19. Founded in 1997, Kiadis Pharma is committed to addressing significant unmet medical needs in the treatment of blood-related conditions.

BSN medical is a prominent manufacturer of medical products headquartered in Luxembourg, specializing in compression therapy, wound care, and orthopaedics. The company develops high-quality branded products designed to provide effective solutions for healthcare providers and patients. BSN medical’s extensive portfolio addresses various health needs, including the treatment of acute, chronic, and challenging wounds, while also focusing on related vascular diseases and lymphology. Their commitment to innovation and technology enables the creation of integrated therapy solutions that facilitate seamless treatment progression, thereby enhancing the overall continuum of care in the healthcare sector.

Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics. During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology. Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.

Atos Medical, founded in 1986, specializes in manufacturing therapeutic devices aimed at enhancing the quality of life for laryngectomized patients. The company produces a range of products, including voice prosthetics, pulmonary rehabilitation devices, adhesives, laryngectomy tubes, and hands-free speaking devices. With its headquarters in Sweden, Atos Medical operates a state-of-the-art clean room and laboratory to support research and development. The company has established a significant international presence, with subsidiaries in multiple countries, including the USA, UK, Germany, Spain, the Netherlands, Belgium, Sweden, and Switzerland, along with exclusive distributors in around 60 countries.

Sapiens Steering Brain Stimulation GmbH is an emerging medical device company whose mission is to deliver superior solutions for deep brain stimulation (DBS) therapy. Sapiens' ambition is to provide a unique, high-resolution, and MRI- compatible DBS system that will improve patient comfort and therapeutic outcome, initially for patients with Parkinson's disease. Sapiens, with offices in Eindhoven, the Netherlands and Munich, Germany, is founded in 2011 as a spin-out of Royal Philips Electronics. Its steering brain stimulation (SBS) system and image-guided programming are based upon patented technologies.

Koole Terminals is an independent international company that specializes in the storage and transportation of liquid bulk products, including vegetable oils and fats, oleochemicals, waxes, biodiesel, base oils, non-hazardous chemicals, and minerals. The company operates eight tank storage terminals and maintains a fleet of twelve barges and three coasters, which provide substantial storage capacity for its diverse range of products. By focusing on energy efficiency and sustainability, Koole Terminals aims to support clients in achieving business growth while contributing to the energy transition towards a more sustainable future.

Argenx is a global immunology company based in the Netherlands, dedicated to enhancing the lives of individuals affected by severe autoimmune diseases and cancer. The company employs advanced antibody engineering technology to develop treatments for rare autoimmune conditions. Its notable product, Vyvgart (efgartigimod), received initial approval in the United States in December 2021 for the treatment of generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022. Through its innovative approaches, Argenx aims to address unmet medical needs in the field of immunology.

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Kreatech Diagnostics is a molecular diagnostics company that specializes in the development and commercialization of innovative detection products for diagnostic and research purposes within the life sciences and healthcare sectors. The company offers a range of Fluorescent in Situ Hybridization (FISH) probes and has established a portfolio for microarray labeling applications. Kreatech utilizes its proprietary non-enzymatic Universal Linkage System labeling technology to enhance the effectiveness of its products, contributing to advancements in molecular diagnostics.

Merus B.V. is a clinical-stage biomedical company focused on the discovery and development of antibody-based biopharmaceuticals, specifically in the field of immuno-oncology. The company utilizes its proprietary Oligoclonics technology to produce a class of human antibodies, which allows for the creation of a mixture of therapeutic antibodies targeting a common antigen from a single cell clone. Additionally, Merus develops bispecific antibody therapeutics known as Biclonics, which are designed to engage multiple targets simultaneously. The company's pipeline includes several product candidates such as MCLA-128, MCLA-117, and MCLA-158, among others, all aimed at addressing various cancer indications.

Kreatech Diagnostics is a molecular diagnostics company that specializes in the development and commercialization of innovative detection products for diagnostic and research purposes within the life sciences and healthcare sectors. The company offers a range of Fluorescent in Situ Hybridization (FISH) probes and has established a portfolio for microarray labeling applications. Kreatech utilizes its proprietary non-enzymatic Universal Linkage System labeling technology to enhance the effectiveness of its products, contributing to advancements in molecular diagnostics.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.

ActoGeniX is a biopharmaceutical company established in 2006 and headquartered in Zwijnaarde, Belgium. It focuses on the development and commercialization of a new generation of biological drugs utilizing a proprietary technology platform. This platform employs living non-pathogenic microorganisms for the oral delivery of biopharmaceuticals, addressing unmet needs in gastrointestinal, immunological, and metabolic diseases. Through its innovative approach, ActoGeniX aims to advance therapeutic options in these critical areas of healthcare.

BMEYE B.V., based in Amsterdam, Netherlands, is a company focused on non-invasive cardiovascular monitoring through the research and development of advanced medical technologies. The company provides a range of products designed to measure blood pressure and cardiac output, including the Finapres and Portapres, which are continuous finger blood pressure monitors, and the Finometer, a stationary device for brachial pressure and hemodynamic assessments. BMEYE also offers BeatScope software for arterial pressure waveform analysis, Modelflow for aortic flow waveform computation, and devices like Cardiopres and Oxyflow for specialized research and clinical applications. Its Nexfin and ccNexfin products are approved for use in the U.S. and Europe, catering to cardiology, anesthesiology, and critical care environments. BMEYE distributes its innovative monitoring solutions through a network of partners, aiming to enhance cardiovascular care and research globally.

Kiadis Pharma N.V. is a biopharmaceutical company based in Amsterdam, the Netherlands, specializing in cell-based immunotherapy products aimed at treating blood cancers and inherited blood disorders. The company is currently advancing K-NK002, which is undergoing Phase II clinical trials for blood cancer patients receiving haploidentical hematopoietic stem cell transplants with the post-transplant cyclophosphamide protocol. Additionally, Kiadis Pharma is developing K-NK003, currently in Phase I/II trials for patients with acute myeloid leukemia relapse or refractory cases. The preclinical product pipeline includes K-NK00X, a natural killer (NK) cell therapy candidate targeting various solid tumors. Kiadis Pharma also collaborates with several institutions, including Harbour BioMed and Erasmus Medical Center, to explore a combination of monoclonal antibodies and natural killer cells as a potential treatment for COVID-19. Founded in 1997, Kiadis Pharma is committed to addressing significant unmet medical needs in the treatment of blood-related conditions.

Scandic Hotels Group is a Sweden-based company specializing in hotel operations, with a network of over 200 hotels across nearly 120 destinations, primarily in the Nordic region. The company caters to both corporate and leisure travelers, with a significant portion of its revenue generated from business travel, conference services, and dining options. Scandic’s geographical reach extends to several countries, including Sweden, Finland, Norway, Denmark, Belgium, Germany, and Poland, with Sweden being the primary source of revenue. The company's diverse offerings aim to accommodate the varying needs of its guests while establishing a strong presence in the hotel industry.

ActoGeniX is a biopharmaceutical company established in 2006 and headquartered in Zwijnaarde, Belgium. It focuses on the development and commercialization of a new generation of biological drugs utilizing a proprietary technology platform. This platform employs living non-pathogenic microorganisms for the oral delivery of biopharmaceuticals, addressing unmet needs in gastrointestinal, immunological, and metabolic diseases. Through its innovative approach, ActoGeniX aims to advance therapeutic options in these critical areas of healthcare.

Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics. During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These products are mainly in the field of genetic disorders, anti-infectives and oncology. Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.

Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient's refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.

BMEYE B.V., based in Amsterdam, Netherlands, is a company focused on non-invasive cardiovascular monitoring through the research and development of advanced medical technologies. The company provides a range of products designed to measure blood pressure and cardiac output, including the Finapres and Portapres, which are continuous finger blood pressure monitors, and the Finometer, a stationary device for brachial pressure and hemodynamic assessments. BMEYE also offers BeatScope software for arterial pressure waveform analysis, Modelflow for aortic flow waveform computation, and devices like Cardiopres and Oxyflow for specialized research and clinical applications. Its Nexfin and ccNexfin products are approved for use in the U.S. and Europe, catering to cardiology, anesthesiology, and critical care environments. BMEYE distributes its innovative monitoring solutions through a network of partners, aiming to enhance cardiovascular care and research globally.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.

Pronota NV is a Belgian company specializing in the development and commercialization of innovative diagnostics aimed at the early detection of life-threatening conditions, such as heart failure, pre-eclampsia, and sepsis. The company utilizes a proprietary protein biomarker diagnostics platform that is non-invasive and validated, focusing on enhancing patient care and addressing unmet medical needs. Founded in 2004 and based in Zwijnaarde, Belgium, Pronota has garnered support from prominent investors and a network of key opinion leaders in the medical field. The firm was previously known as Peakadilly NV before rebranding in 2006.

DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).

OctoPlus is a specialty pharmaceutical company globally renowned for its expertise in pharmaceutical development of injectables and is based on the bioscience park, one of the leading bioscience industry parks in Europe. The company employs around 120 people, and is highly culturally diverse, with over 20 different nationalities represented in its workforce.

PamGene is a biotechnology company that specializes in a proprietary array-based platform designed to measure the activities of kinases and nuclear receptors. This technology enhances the understanding of drug interactions with these critical signaling molecules. PamGene's platform has diverse applications, including lead identification and optimization, clinical translational research, and biomarker development, particularly in the fields of oncology and medicine. The company's focus is on measuring the activities of tyrosine and serine-threonine kinases, alongside nuclear receptors, while also providing software tools for data analysis. This enables researchers to discover and develop medicines that can inhibit or modulate cellular kinases and their associated pathways.

PamGene is a biotechnology company that specializes in a proprietary array-based platform designed to measure the activities of kinases and nuclear receptors. This technology enhances the understanding of drug interactions with these critical signaling molecules. PamGene's platform has diverse applications, including lead identification and optimization, clinical translational research, and biomarker development, particularly in the fields of oncology and medicine. The company's focus is on measuring the activities of tyrosine and serine-threonine kinases, alongside nuclear receptors, while also providing software tools for data analysis. This enables researchers to discover and develop medicines that can inhibit or modulate cellular kinases and their associated pathways.

Haanpaa provides trucks that distribute chemical products across Europe. It offers services in their storage, maintenance, transportation, and delivery in several European cities. Haanpaa specializes as well in sampling, monitoring, and packaging chemical products. Moreover, it provides tank inspection and customer services. Haanpaa produces specialty chemicals, pulps and papers, fuels, lubricants, animal feeds, agricultural commodities, and other products. Jussi Haanpaa founded Haanpaa in 1949, with its headquarters in Vantaa in Finland. Haanpaa has branches in Oulu and Hamina in Finland; Helsingborg and Göteborg in Sweden, Fredrikstad in Norway, Tallinn in Estonia, Saint Petersburg and Moscow in Russia, and Barendrecht in the Netherlands. It now operates as a subsidiary of Groupe Samat SA since July 12, 2016.